Marc A. Bjurlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc A. Bjurlin has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
Richard S. Matulewicz
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
14 shared publications- Samir S. Taneja
NYU Langone Health
12 shared publications - William C. Huang
NYU Langone Health, New York, NY
12 shared publications Hung-Jui Tan
10 shared publicationsTracy L. Rose
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA
10 shared publicationsAudrey Renson
Department of Clinical Research NYU Langone Hospital – Brooklyn Brooklyn New York USA
9 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 2015-2023
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years
PURPOSE: The causal link between smoking and bladder cancer (BC) development is well established but the long-term impact of tobacco taxation and health policy on BC mortality and disability-adjusted life years (DALYs) has not been fully elucidated. Given the protracted latency of carcinogenesis, this study examines whether historical changes in tobacco taxation and smoke-free laws are associated with reductions in BC disease burden and mortality in the United States. METHODS: Smoking-attributable BC mortality and DALY data, and federal and state tobacco taxation data were differenced as time series to achieve stationarity. Cross-correlation analysis identified optimal lag times. A semilogarithmic multivariable linear regression was used to estimate the percent change in BC outcomes per 1% increase in tobacco tax. Analyses were adjusted for national health expenditures and stratified by state. RESULTS: The median lag time between tobacco tax changes and smoking-attributable BC mortality was 17 years, whereas the lag to DALYs was 24 years. National-level regression showed no significant association between taxation and BC mortality (–0.09%, P = .64) or DALYs (1.77%, P = .051). However, 22 states exhibited significant reductions in mortality, with the greatest observed in Arkansas (–3.64%, P < .001), California, and Indiana. Sixteen states showed significant DALY reductions, led by California (–4.68%). The implementation of smoke-free laws alone was not associated with decreases in smoking-attributable BC mortality and DALY. CONCLUSION: Tobacco taxation is significantly associated with long-term reductions in smoking-attributable BC mortality and DALYs at the state level, but not nationally. These findings demonstrate the importance of adjunctive localized public health policy and the delayed impact of tobacco control measures on cancer outcomes. Further investigation is warranted to understand the mechanisms driving state-level variability and to inform targeted prevention strategies.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 2015-2023
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years
PURPOSE: The causal link between smoking and bladder cancer (BC) development is well established but the long-term impact of tobacco taxation and health policy on BC mortality and disability-adjusted life years (DALYs) has not been fully elucidated. Given the protracted latency of carcinogenesis, this study examines whether historical changes in tobacco taxation and smoke-free laws are associated with reductions in BC disease burden and mortality in the United States. METHODS: Smoking-attributable BC mortality and DALY data, and federal and state tobacco taxation data were differenced as time series to achieve stationarity. Cross-correlation analysis identified optimal lag times. A semilogarithmic multivariable linear regression was used to estimate the percent change in BC outcomes per 1% increase in tobacco tax. Analyses were adjusted for national health expenditures and stratified by state. RESULTS: The median lag time between tobacco tax changes and smoking-attributable BC mortality was 17 years, whereas the lag to DALYs was 24 years. National-level regression showed no significant association between taxation and BC mortality (–0.09%, P = .64) or DALYs (1.77%, P = .051). However, 22 states exhibited significant reductions in mortality, with the greatest observed in Arkansas (–3.64%, P < .001), California, and Indiana. Sixteen states showed significant DALY reductions, led by California (–4.68%). The implementation of smoke-free laws alone was not associated with decreases in smoking-attributable BC mortality and DALY. CONCLUSION: Tobacco taxation is significantly associated with long-term reductions in smoking-attributable BC mortality and DALYs at the state level, but not nationally. These findings demonstrate the importance of adjunctive localized public health policy and the delayed impact of tobacco control measures on cancer outcomes. Further investigation is warranted to understand the mechanisms driving state-level variability and to inform targeted prevention strategies.
- 5 October 2026
- Published by Wolters Kluwer Health in Journal of Urology
Multi-Cancer Early Detection Tests and Prostate Cancer Screening: Navigating the Gaps
- 5 October 2026
- Published by Wolters Kluwer Health in Journal of Urology
Multi-Cancer Early Detection Tests and Prostate Cancer Screening: Navigating the Gaps
- 12 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (3) , 318-320
Blinded by the Smoke: Are We Ignoring a Key Modifier of Response in NMIBC Trials?
- 12 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (3) , 318-320
Blinded by the Smoke: Are We Ignoring a Key Modifier of Response in NMIBC Trials?
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (3)
Letter: The Bladder Is Not an Island
- 1 March 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (3)
Open AccessLetter: The Bladder Is Not an Island
- Open Access
- 1 January 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (1)
Systematic review: The role of bicarbonate therapy after urinary diversion
Background: Radical cystectomy (RC) with urinary diversion remains the standard of care for muscle invasive bladder cancer. While metabolic acidosis (MA) after RC is common, the relationship between MA, post-operative complications, and the impact of bicarbonate supplementation remains unclear. Objective: To review the role of bicarbonate therapy for MA following RC. Methods: We performed a comprehensive systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines analyzing MA after RC. We included randomized controlled trials and cohort studies that reported metabolic acidosis complications and studies that utilized bicarbonate therapy peri-operatively. Our primary outcome was metabolic acidosis or role of metabolic acidosis as it relates to bicarbonate therapy or post-operative complications. Results: Twenty-nine studies were identified to investigate MA in the setting of postoperative complication rates or the role of bicarbonate treatment in peri-operative pathways. 19 studies evaluated the incidence of MA without intervention, 5 studies supplemented bicarbonate therapy for patients meeting specific criteria, and 5 studies utilized a standardized postoperative bicarbonate therapy regimen. The incidence of post-operative metabolic acidosis ranged from 1–86% after continent urinary diversion and 1–27% after ileal conduit urinary diversion. Post-operative renal function, diabetes, and older age were factors associated with metabolic acidosis. There was lack of uniformity, indications, or consistent outcomes for utilizing postoperative bicarbonate therapy. Conclusion: There is little uniformity regarding the role of supplemental bicarbonate therapy and its impact on post-operative complications following urinary diversion. Future studies are needed to better evaluate the role MA plays in peri-operative RC pathways.
- 1 January 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (1)
Open AccessSystematic review: The role of bicarbonate therapy after urinary diversion
Background: Radical cystectomy (RC) with urinary diversion remains the standard of care for muscle invasive bladder cancer. While metabolic acidosis (MA) after RC is common, the relationship between MA, post-operative complications, and the impact of bicarbonate supplementation remains unclear. Objective: To review the role of bicarbonate therapy for MA following RC. Methods: We performed a comprehensive systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines analyzing MA after RC. We included randomized controlled trials and cohort studies that reported metabolic acidosis complications and studies that utilized bicarbonate therapy peri-operatively. Our primary outcome was metabolic acidosis or role of metabolic acidosis as it relates to bicarbonate therapy or post-operative complications. Results: Twenty-nine studies were identified to investigate MA in the setting of postoperative complication rates or the role of bicarbonate treatment in peri-operative pathways. 19 studies evaluated the incidence of MA without intervention, 5 studies supplemented bicarbonate therapy for patients meeting specific criteria, and 5 studies utilized a standardized postoperative bicarbonate therapy regimen. The incidence of post-operative metabolic acidosis ranged from 1–86% after continent urinary diversion and 1–27% after ileal conduit urinary diversion. Post-operative renal function, diabetes, and older age were factors associated with metabolic acidosis. There was lack of uniformity, indications, or consistent outcomes for utilizing postoperative bicarbonate therapy. Conclusion: There is little uniformity regarding the role of supplemental bicarbonate therapy and its impact on post-operative complications following urinary diversion. Future studies are needed to better evaluate the role MA plays in peri-operative RC pathways.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (1) , 44-56
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer
In QUILT-3.032, the efficacy of IL-15 receptor agonist, nogapendekin alfa inbakicept (NAI) in combination with BCG for BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) was assessed. Herein we report the 36-month follow-up among participants with BCG-unresponsive papillary disease (Cohort B). NCT03022825 is an open-label, multi-center study with BCG-unresponsive high-grade Ta/T1 papillary NMIBC who received 400μg NAI plus 50mg BCG intravesically weekly for six consecutive weeks. The primary endpoint is disease-free survival (DFS) at 12-months. Progression-free survival (PFS), disease-specific survival (DSS), and cystectomy avoidance were assessed. Treatment-related adverse events (TRAEs) were assessed. At July 15, 2024 data cutoff, the DFS rates at 12-, 24-, and 36-months were 58.2% (95% CI 46.6, 68.2), 52.1% (95% CI 40.3, 62.7), and 38.2% (95% CI 25.6, 50.6), respectively. The PFS rates at 12- and 36-months were 94.9% (95% CI 86.9, 98.0) and 83.1% (95% CI 69.5, 91.0). The DSS rates at 12- and 36-months were 98.7% (95% CI 91.4, 99.8) and 96.0% (95% CI 88.2, 98.7). The median DSS has not been reached. Cystectomy avoidance rates at 12- and 36-months were 92.2% (95% CI 83.4, 96.4) and 81.8% (95% CI 68.1, 90.1), with median time to cystectomy not reached. Most TRAEs were grade 1-2 (61%) with 3% grade 3, and no grade 4-5. The 12- and 36-month DFS, PFS, DSS, and cystectomy avoidance rates demonstrate the effectiveness and safety of NAI plus BCG in the management of BCG-unresponsive papillary disease.
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (1) , 44-56
Top Cited PapersOpen AccessProlonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer
In QUILT-3.032, the efficacy of IL-15 receptor agonist, nogapendekin alfa inbakicept (NAI) in combination with BCG for BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) was assessed. Herein we report the 36-month follow-up among participants with BCG-unresponsive papillary disease (Cohort B). NCT03022825 is an open-label, multi-center study with BCG-unresponsive high-grade Ta/T1 papillary NMIBC who received 400μg NAI plus 50mg BCG intravesically weekly for six consecutive weeks. The primary endpoint is disease-free survival (DFS) at 12-months. Progression-free survival (PFS), disease-specific survival (DSS), and cystectomy avoidance were assessed. Treatment-related adverse events (TRAEs) were assessed. At July 15, 2024 data cutoff, the DFS rates at 12-, 24-, and 36-months were 58.2% (95% CI 46.6, 68.2), 52.1% (95% CI 40.3, 62.7), and 38.2% (95% CI 25.6, 50.6), respectively. The PFS rates at 12- and 36-months were 94.9% (95% CI 86.9, 98.0) and 83.1% (95% CI 69.5, 91.0). The DSS rates at 12- and 36-months were 98.7% (95% CI 91.4, 99.8) and 96.0% (95% CI 88.2, 98.7). The median DSS has not been reached. Cystectomy avoidance rates at 12- and 36-months were 92.2% (95% CI 83.4, 96.4) and 81.8% (95% CI 68.1, 90.1), with median time to cystectomy not reached. Most TRAEs were grade 1-2 (61%) with 3% grade 3, and no grade 4-5. The 12- and 36-month DFS, PFS, DSS, and cystectomy avoidance rates demonstrate the effectiveness and safety of NAI plus BCG in the management of BCG-unresponsive papillary disease.